Ranok Therapeutics (hangzhou) Co., Ltd.
Clinical trials sponsored by Ranok Therapeutics (hangzhou) Co., Ltd., explained in plain language.
-
New drug targets tough pancreatic cancer mutation in 60-Patient trial
Disease control Recruiting nowThis study tests an experimental drug called RNK08954 in 60 adults with advanced pancreatic cancer that has a specific genetic change (KRAS G12D). The goal is to see if the drug can shrink tumors or slow cancer growth, and to check for side effects. Participants must have a confi…
Phase: PHASE2 • Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New pill targets hard-to-treat cancer mutation in early human trial
Disease control Recruiting nowThis study tests an experimental drug called RNK08954 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to find a safe dose and see if the drug can shrink tumors or slow the disease. About 152 adults who have already tried stan…
Phase: PHASE1, PHASE2 • Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC